CLK1: A Drug Target / Disease Biomarker (G1195)

Target Name: CLK1

NCBI ID: G1195

CLK1

CLK1: A Drug Target / Disease Biomarker

CLK1, also known as Calbindin, is a protein that is expressed in a variety of tissues throughout the body. It is a key regulator of the cell division process, and is involved in the development and maintenance of tissues such as muscle, bone, and brain. CLK1 has also been shown to play a role in the regulation of pain perception and the development of certain diseases, such as cancer.

CLK1 is a protein that is expressed in a variety of tissues throughout the body, including muscle, bone, and brain. It is a key regulator of the cell division process, and is involved in the development and maintenance of tissues such as muscle, bone, and brain. CLK1 has also been shown to play a role in the regulation of pain perception and the development of certain diseases, such as cancer.

One of the functions of CLK1 is to regulate the cell division process. CLK1 is a key regulator of the G1/S transition, which is the stage of cell division where the cell prepares for cell division. During the G1 phase, CLK1 helps to ensure that the cell has enough copies of its genetic material to divide. It does this by activating the G1 kinase, which is responsible for activating the G1 phase.

CLK1 is also involved in the regulation of cell growth. It helps to ensure that cells do not grow too large, which is important for maintaining the structure and function of tissues. CLK1 does this by regulating the activity of the cell growth factor, which is responsible for controlling the growth of cells.

In addition to its role in cell division and growth, CLK1 is also involved in the regulation of pain perception. CLK1 is known to play a role in the regulation of pain perception, and is often used as a drug target for the treatment of pain. CLK1 is thought to work by interacting with the neurotransmitter GABA, which is involved in the regulation of pain perception.

CLK1 is also involved in the regulation of the development and progression of certain diseases, such as cancer. CLK1 has been shown to be involved in the regulation of the angiogenesis process, which is the process by which cancer cells develop blood vessels to supply them with oxygen and nutrients. CLK1 is thought to work by regulating the activity of the vascular endothelial growth factor (VEGF), which is involved in the development of blood vessels.

In conclusion, CLK1 is a protein that is expressed in a variety of tissues throughout the body. It is a key regulator of the cell division process, and is involved in the development and maintenance of tissues such as muscle, bone, and brain. CLK1 is also involved in the regulation of pain perception and the development of certain diseases, such as cancer. Therefore, CLK1 is a potential drug target for the treatment of these conditions.

Protein Name: CDC Like Kinase 1

Functions: Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates: SRSF1, SRSF3 and PTPN1. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells and adenovirus E1A pre-mRNA

The "CLK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets